A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia
A Study to Test if TV-46000 is Effective for Maintenance Treatment of Schizophrenia
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Enrolling: Male and Female Patients
IRB Number: 7685
U.S. Govt. ID: NCT03503318
Contact: Marlene Carlson, MPH: 646-774-8436 / mc157@columbia.edu
Additional Study Information: The purpose of this study is to evaluate the efficacy, safety and tolerability of different doses and durations of TV-46000 given by subcutaneous (under the skin) injection as compared to placebo for use as a potential maintenance in adults with schizophrenia.
This study is closed
Joshua Kantrowitz, MD
Do You Qualify?
Do you have schizophrenia? Yes No
Are you between the ages of 18 - 55? Yes No
Are you / have you been on Clozapine? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Marlene Carlson, MPH